Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Etrumadenant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A known ✓ | P29274 | 20/20 | 1.00 |
| ▸ | ADORA2B known ✓ | P29275 | 17/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Etrumadenant SCHEMBL29560949 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2BADORA1 | |
| Etrumadenant SCHEMBL29659112 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2BADORA1 | |
| Etrumadenant SCHEMBL29393659 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2BADORA1 | |
| Etrumadenant SCHEMBL29653560 | 0.94 | ADORA2A (0.89) | ADORA2AADORA2BADORA1 | |
| SCHEMBL20417111 | 0.93 | ADORA2A (0.87) | ADORA2AADORA2BADORA1 | |
| SCHEMBL20401123 | 0.91 | ADORA2A (0.83) | ADORA2AADORA2BADORA1 | |
| SCHEMBL20436497 | 0.91 | ADORA2A (0.83) | ADORA2AADORA2BADORA1 | |
| SCHEMBL20401417 | 0.91 | ADORA2A (0.83) | ADORA2AADORA2BADORA1 | |
| SCHEMBL20401229 | 0.89 | ADORA2A (0.80) | ADORA2AADORA2BADORA1 | |
| SCHEMBL20417122 | 0.89 | ADORA2A (0.79) | ADORA2AADORA2BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059293-A1 | CD73 INHIBITOR AND A2A/A2B ADENOSINE RECEPTOR INHIBITOR COMBINATION THERAPY | INCYTE CORPORATION | 2025-02-20 | — | — | US | claimed |
| US-20240368183-A1 | Macrocyclic Compounds Having ENT1 Inhibiting Activity | iTeos Belgium SA (BE) | 2024-11-07 | — | — | US | claimed |
| US-12060433-B2 | CD73 inhibitor and A2A/A2B adenosine receptor inhibitor combination therapy | INCYTE CORPORATION (US) | 2024-08-13 | — | — | US | claimed |
| CN-118076610-A | Macrocyclic compounds with ENT1 inhibitory activity | ITEOS比利时公司 | 2024-05-24 | — | — | CN | claimed |
| CN-117500503-A | Combination therapy comprising an A2A/A2B inhibitor, a PD-1/PD-L1 inhibitor and an anti-CD 73 antibody | 因赛特公司 | 2024-02-02 | — | — | CN | claimed |
| CN-116535365-A | Macrocyclic diamine derivatives and their combination with adenosine receptor antagonists as ENT inhibitors for the treatment of cancer | ITEOS比利时公司 | 2023-08-04 | — | — | CN | claimed |
| US-20230203058-A1 | MACROCYCLIC DIAMINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | iTeos Belgium SA (BE) | 2023-06-29 | — | — | US | claimed |
| US-20230146675-A1 | PYRIMIDO[5,4-d]PYRIMIDINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | iTeos Belgium SA (BE) | 2023-05-11 | — | — | US | claimed |
| CN-115996927-A | Pyrimido [5,4-d ] pyrimidine derivatives and combinations with adenosine receptor antagonists as ENT inhibitors for the treatment of cancer | ITEOS比利时公司 | 2023-04-21 | — | — | CN | claimed |
| CN-115768773-A | Macrocyclic diamine derivatives as ENT inhibitors for the treatment of cancer and combinations thereof with adenosine receptor antagonists | ITEOS比利时公司 | 2023-03-07 | — | — | CN | claimed |
| EP-4132933-A1 | MACROCYCLIC DIAMINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | iTeos Belgium SA (BE) | 2023-02-15 | — | — | EP | claimed |
| CN-115551595-A | Combination therapy of a CD73 inhibitor and an A2A/A2B adenosine receptor inhibitor | 因赛特公司 | 2022-12-30 | — | — | CN | claimed |
| US-20210338672-A1 | USE OF AN INHIBITOR OF AN ENT FAMILY TRANSPORTER IN THE TREATMENT OF CANCER AND COMBINATION THEREOF WITH AN ADENOSINE RECEPTOR ANTAGONIST | iTeos Belgium SA (BE) | 2021-11-04 | — | — | US | claimed |
| EP-3856181-A1 | USE OF AN INHIBITOR OF AN ENT FAMILY TRANSPORTER IN THE TREATMENT OF CANCER AND COMBINATION THEREOF WITH AN ADENOSINE RECEPTOR ANTAGONIST | iTeos Belgium SA (BE) | 2021-08-04 | — | — | EP | claimed |
| US-20210230294-A1 | CD73 INHIBITOR AND A2A/A2B ADENOSINE RECEPTOR INHIBITOR COMBINATION THERAPY | INCYTE CORPORATION | 2021-07-29 | — | — | US | claimed |
| CN-113164462-A | Use of inhibitors of ENT family transporters in cancer therapy and combinations thereof with adenosine receptor antagonists | ITEOS比利时公司 | 2021-07-23 | — | — | CN | claimed |
| WO-2020065036-A1 | USE OF AN INHIBITOR OF AN ENT FAMILY TRANSPORTER IN THE TREATMENT OF CANCER AND COMBINATION THEREOF WITH AN ADENOSINE RECEPTOR ANTAGONIST | ITEOS THERAPEUTICS S.A. (BE) | 2020-04-02 | — | — | WO | claimed |
| US-12630526-B2 | Processes for preparing aminopyrimidine compounds | ARCUS BIOSCIENCES, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| WO-2018136700-A1 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | ARCUS BIOSCIENCES, INC. (US) | 2018-07-26 | — | — | WO | disclosed |
| WO-2018136700-A1 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | ARCUS BIOSCIENCES, INC. (US) | 2018-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368183-A1 | Macrocyclic Compounds Having ENT1 Inhibiting Activity | ENTPD5, ENTPD1, ENTPD8 | ADORA2A 1396/4885ADORA2B 2091/4885ADORA1 603/4885 |
| US-12630526-B2 | Processes for preparing aminopyrimidine compounds | PAICS, CCNL2, UCK2 | ADORA2A 662/4885ADORA2B 461/4885ADORA1 711/4885 |
| US-12060433-B2 | CD73 inhibitor and A2A/A2B adenosine receptor inhibitor combination therapy | ADORA2A, ADORA2B, NT5E | ADORA2A 1/4885ADORA2B 2/4885ADORA1 10/4885 |
| US-20230203058-A1 | MACROCYCLIC DIAMINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | ENTPD1, SLC29A1, ENTPD5 | ADORA2A 10/4885ADORA2B 14/4885ADORA1 7/4885 |
| US-20250059293-A1 | CD73 INHIBITOR AND A2A/A2B ADENOSINE RECEPTOR INHIBITOR COMBINATION THERAPY | ADORA2A, ADORA2B, NT5E | ADORA2A 1/4885ADORA2B 2/4885ADORA1 10/4885 |
| US-20230146675-A1 | PYRIMIDO[5,4-d]PYRIMIDINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | ENTPD5, ENTPD1, SLC29A1 | ADORA2A 17/4885ADORA2B 32/4885ADORA1 9/4885 |
| US-20210230294-A1 | CD73 INHIBITOR AND A2A/A2B ADENOSINE RECEPTOR INHIBITOR COMBINATION THERAPY | ADORA2A, ADORA2B, NT5E | ADORA2A 1/4885ADORA2B 2/4885ADORA1 10/4885 |
| US-20210338672-A1 | USE OF AN INHIBITOR OF AN ENT FAMILY TRANSPORTER IN THE TREATMENT OF CANCER AND COMBINATION THEREOF WITH AN ADENOSINE RECEPTOR ANTAGONIST | SLC29A1, SLC29A2, ENTPD5 | ADORA2A 11/4885ADORA2B 18/4885ADORA1 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.